While research on hematological malignancies has lagged behind that of solid tumors due to their stronger heterogeneity and complexity, the emergence of single-cell sequencing technology provides a crucial platform for better understanding these diseases. It enables the characterization of tumor cell heterogeneity, clonal evolution, epigenomic variation, the tumor microenvironment composition, and cell interactions, potentially bridging knowledge gaps. Leukemia is a common malignant tumor of the blood system in children, with B-ALL accounting for the majority of cases. Minimal residual disease (MRD) is a key prognostic indicator for pediatric B-ALL, yet detecting low-abundance residual cancer cells remains a technical challenge limiting insights into drug resistance mechanisms maintained by MRD.
Download Now
The field is required.
I agree that Novogene Corporation may use this information to contact me to assist with my request. I understand that all personal information I have submitted will be kept confidential in accordance with Novogene's privacy policy.